AndreyPopov/iStock via Getty Images Vanda Pharmaceuticals ( NASDAQ: VNDA ) rejected a sweetened takeover offer from Future Pak. Vanda ( VNDA ) said the offer for $7.25 to $7.
75 per share in cash plus certain contingent value rights "substantially undervalues" the company, according to a statement on Friday. Future Pak earlier this month said that its latest offer represented a t otal consideration of $11.62 to $12.
12 per share . "The board believes the revised unsolicited proposal is yet another opportunistic attempt to purchase the company's shares at a discount to Vanda's intrinsic value," Vanda said in the statement. More on Vanda Pharmaceuticals Vanda Pharmaceuticals, Inc.
(VNDA) Q1 2024 Earnings Call Transcript Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much Vanda reports positive Phase 3 data for motion sickness drug Vanda Pharmaceuticals GAAP EPS of -$0.07, revenue of $47.46M Seeking Alpha’s Quant Rating on Vanda Pharmaceuticals.
